KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation and Depletion (2016 - 2022)

TherapeuticsMD's Depreciation and Depletion history spans 13 years, with the latest figure at $200000.0 for Q4 2022.

  • For Q4 2022, Depreciation and Depletion rose 200.0% year-over-year to $200000.0; the TTM value through Sep 2023 reached $200000.0, down 33.33%, while the annual FY2022 figure was $600000.0, 50.0% up from the prior year.
  • Depreciation and Depletion reached $200000.0 in Q4 2022 per TXMD's latest filing, roughly flat from $200000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $200000.0 in Q2 2020 to a low of -$200000.0 in Q4 2021.
  • Average Depreciation and Depletion over 5 years is $124020.6, with a median of $187625.0 recorded in 2019.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 200.5% in 2020, then plummeted 200.0% in 2021.
  • A 5-year view of Depreciation and Depletion shows it stood at $59989.0 in 2018, then soared by 193.8% to $176250.0 in 2019, then increased by 13.48% to $200000.0 in 2020, then tumbled by 200.0% to -$200000.0 in 2021, then skyrocketed by 200.0% to $200000.0 in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Depreciation and Depletion are $200000.0 (Q4 2022), $200000.0 (Q3 2022), and $200000.0 (Q2 2022).